Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. Actively turning 'COLD' tumors 'HOT'.
Reovirus is a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus commonly found in environmental waters. It is widely hosted and typically only affects the gastrointestinal or respiratory system, with symptoms much like a common cold or the flu, depending on severity.
Clinical trials have provided us with a multitude of observations and conclusions thus far regarding the effectiveness of pelareorep in normal cells versus cancerous cells.